Tiefenbacher Pharmaceuticals successfully prepared the launch of the analgesic Buprenorphine as Transdermal Patch in Australia.

We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable and available for all patients around the world. A key point here is that this applies to everyone, regardless of their nationality or income. That´s why we are thrilled to share that we have successfully prepared the launch of the generic version of the analgesic Buprenorphine as Transdermal Patch in Australia.

Affordable Medicines (fka Generics) are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. The low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending.

Buprenorphine belongs to a class of drugs known as opioid analgesics. Buprenorphine patches are used to help relieve severe and persistent pain (such as due to arthritis or chronic back pain). Our cooperation partner marketed the Transdermal Patches in the strengths 5mcg, 10mcg, 15mcg, and 20mcg. This product has already been launched in several international markets before.

The successful launch of this affordable medicine is a testament to the hard work and dedication of our team. We are particularly excited about the positive impact for the Australian healthcare system and look already forward to further market entries of our high-quality medicines.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.  

For more information about our finished dosage forms (FDF) including highly potent drugs and e-healthcare solutions, please contact us at  info@tiefenbacher.com or visit us on  www.tiefenbacher-pharmaceuticals.com

Tiefenbacher New Market Launch: Buprenorphine in Australia
About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company. We are providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP please contact us by email at info@tiefenbacher.com or visit us on:  www.tiefenbachergroup.com